The aim is to reduce the biopharma’s R&D workforce by more than 35% compared with 2025 levels, with the associated cost ...

Vivoryon Therapeutics has regained the China rights to its kidney disease prospect as the German biotech’s cash reserves ...

MetaVia has linked its GLP-1/glucagon receptor agonist to reductions in liver fat and body weight in a phase 1 trial.

Evommune has agreed to pay $30 million to China’s Hinova Pharmaceuticals to get stuck into a niche of preclinical molecular ...

AbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase ...

Ultragenyx is laying off 20% of its workforce and axing drug development programs to cut its annual R&D budget to half of the ...

Originally, Rhythm licensed the melanocortin 4 receptor (MC4R) candidate, known at the time as LB54640, from LG for $80 ...

Charles River Laboratories’ virtual control group (VCG) database will be used in a toxicology study run by French biopharma ...

AbbVie has scrapped a phase 2 solid tumor drug after deciding that the monoclonal antibody was unlikely to best the current ...

Philips recorded a provision of 288 million euros ($322 million) for the proposed settlement in the third quarter, with payment “expected in the first quarter of 2027.” A separate investigation by U.S ...

Pfizer has axed a phase 2 pulmonary arterial hypertension program on business grounds, dealing a setback to a long-running ...

Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...